Background {#Sec1}
==========

Colorectal cancer (CRC) is a common gastrointestinal malignancy, with the third highest incidence and fourth highest mortality among malignant tumors worldwide \[[@CR1], [@CR2]\]. Since the early symptoms of CRC are obscure, majority of the patients are diagnosed in the intermediate and late stages, and suffer from metastasis at diagnosis, with a 5-year survival rate \< 10%. Chemotherapy is the main treatment method for CRC \[[@CR3]--[@CR5]\].

Irinotecan-based chemotherapy is a standard first-line or second-line regimen for the treatment of mCRC. However, irinotecan has dose-limiting toxicities, mainly neutropenia and delayed-onset diarrhea, wherein the incidence of grade 3\~4 delayed-onset diarrhea and neutropenia is high. Studies have shown that *UGT1A1* gene polymorphism is differently distributed among different ethnicities, which may lead to different toxicities and efficacies of irinotecan \[[@CR6]\]. Even with the same ethnicity, the gene frequency differs in varying geographical regions \[[@CR7]\]. Moreover, the frequency of gene mutation differs among various ethnic groups due to different genetic backgrounds. Thus, the therapeutic regimen of irinotecan should be individualized for different ethnic groups, rather than referring to the guidelines of Europe or America for Chinese Han patients. This study aimed to analyze the distribution of *UGT1A1* gene polymorphisms in mCRC patients of Guangxi Zhuang, as well as the correlation of *UGT1A1* gene polymorphisms with the adverse reactions and efficacy of irinotecan chemotherapy, in order to develop an individualized irinotecan regimen for mCRC patients of Guangxi Zhuang.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

A total of 406 mCRC patients receiving initial treatment in four centers of Guangxi between June 01, 2013 and June 01, 2015 were selected. After three generations of strict screening, 102 patients were found to be fully compliant with the criteria of Chinese Zhuang, of which 16 were excluded due to severe diseases and incomplete follow-up data. Eligibility criteria included: 1) Patients were diagnosed as mCRC by pathological and imaging results, and did not previously receive chemoradiotherapy; 2) Patients were Guangxi Zhuang for three generations; 3) Patients had measurable lesions by MRI or CT examination; 4) Patients had a ECOG PS ≤1 point, with an expected survival of ≥3 months; 5) Patients did not have significant contraindications to chemotherapy in routine blood, liver and kidney function, ECG and other examinations prior to chemotherapy; 6) Patients had no history of other malignancies; 7) Patients signed informed consent; 8) Patients were routinely followed-up. The selected patients were aged 21\~76 years (median age: 56 years), and their clinical data are listed in Table [1](#Tab1){ref-type="table"}. This study was approved by the local ethics committee. Informed consent was obtained from all individual participants included in the study. Table 1Clinical characteristics of patients with mCRCVariableNumberPercentage (%)Age (years)  \< 604957.0  ≥ 603743.0Gender Male5462.8 Female3237.2PS score 02933.7 15766.3Tumor site Colon3641.9 Rectum5058.1Number of metastatic sites 15159.3  ≥ 23540.7

Treatment regimen {#Sec4}
-----------------

### *UGT1A1* genotyping {#Sec5}

Genotyping studies were performed by an independent laboratory (Department of Clinical Pharmacology, Xiangya Hospital, Central South University), and 2 mL peripheral blood was collected in an EDTA containing glass tube about 1 week before the first chemotherapy. Subsequently, genomic DNA was extracted using the phenol-chloroform method, the target gene fragment was amplified using PCR, and the PCR products were sequenced by pyrosequencing. The *UGT1A1*\*28 and \*6 polymorphisms were read using the SNP analysis software.

Chemotherapy regimen {#Sec6}
--------------------

The selected patients received a first-line chemotherapy with irinotecan (CPT-11) + 5-Fluorouracil (5-Fu)/LV (FOLFIRI) regimen. The dosage and administration were as follows: patients were given intravenous infusion of irinotecan (180 mg/m2, 90 mins),d1,intravenous infusion of LV (400 mg/m2),d1, and intravenous injection of 5-Fu (400 mg/m2),d1. Then, the patients were given continuous intravenous injection of 5-Fu (2400 mg/m2),46\~48 h. All the treatment were repeated every 2 weeks for 4\~6 cycles. The efficacy was evaluated after patients were given at least four cycles of treatment.

Response and toxicity evaluation {#Sec7}
--------------------------------

The follow-up ranged from 31\~55 months with a median 40 months as of Jan 2018. Four cases were lost to follow-up, with a follow-up rate of 95.56%. The primary endpoint of this study was toxicity, and the secondary endpoint included short-term efficacy and progression-free survival (PFS). The efficacy was evaluated according to the response evaluation criteria in solid tumors, Revised RECIST guidelines (version 1.1) \[[@CR8]\]. The adverse reactions were evaluated according to the evaluation and classification of neutropenia, delayed diarrhea in National Cancer Institute NCI-CTC (version 3.0) \[[@CR9]\].

Endpoints and statistical analysis {#Sec8}
----------------------------------

All SNPs were analyzed for deviation from Hardy-Weinberg equilibrium (HWE),and the genotype and allelic frequencies were calculated. Two-tailed Fisher's exact test was used to calculate the genotype distribution in controls and patients, and to compare the differences between both groups; χ2 test or Fisher exact probability was used to analyze the adverse reactions and efficacy. Logistic regression was adopted to analyze the relationship between the clinical characteristics of patients and the adverse reactions of irinotecan. Kaplan-Meier method was used to plot the survival curve as well as analyze the relationship between different genotypes and PFS.

Results {#Sec9}
=======

Distribution of the *UGT1A1* genotype {#Sec10}
-------------------------------------

The genotype distribution of *UGT1A1* gene\*28 and \*6 in 86 patients was consistent with the Hardy-Weinberg equilibrium (HWE) (*p* \> 0.1) in population genetics, as shown in Table [2](#Tab2){ref-type="table"}. For the *UGT1A1*\*28, there were 60 cases (69.8%) of wild-type (TA6/6), 26 cases (30.2%) of heterozygous--type (TA6/7), and no case of homozygous-type (TA7/7). The sequencing results are shown in Fig. [1](#Fig1){ref-type="fig"}. For the *UGT1A1*\*6, there were 66 cases (76.7%) of wild-type (G/G), 18 cases (20.9%) of heterozygous--type (G/A) and two cases (2.3%) of homozygous-type (A/A). The sequencing results are shown in Fig. [2](#Fig2){ref-type="fig"}. Table 2Distribution of UGT1A1 genotype in Guangxi ZhuangVariableNumber (%)Allelic frequenciesH-W equilibrium pUGT1A1\*28 Wild TA6/660 (69.8)TA6 0.8490.306 Heterozygous TA6/726 (30.2)TA7 0.151 Homozygous TA7/70 (0)UGT1A1\*6 Wild (G/G)66 (76.7)G 0.8720.834 Heterozygous (G/A)18 (20.9)A 0.128 Homozygous (A/A)2 (2.3)Fig. 1Sequencing results of *UGT1A1*\*28 gene polymorphism. *UGT1A1*\*28 wild-type (**a**), heterozygous-type (**b**)Fig. 2Sequencing results of *UGT1A1*\*6 gene polymorphism. *UGT1A1*\*6 wild-type (**a**), heterozygous--type (**b**), homozygous-type (**c**)

Toxicity to chemotherapy based on the *UGT1A1* genotype {#Sec11}
-------------------------------------------------------

Among the 86 patients, there were 60 cases of *UGT1A1*\*28 TA6/6, of which seven cases (11.7%) experienced grade 3\~4 delayed-onset diarrhea and nine cases (15.0%) had grade 3\~4 neutropenia. Among the 26 cases of *UGT1A1*\*28 TA6/7, nine cases (34.6%) experienced grade 3\~4 delayed-onset diarrhea and eight cases (30.8%) had grade 3\~4 neutropenia. Statistical analysis revealed that *UGT1A1*\*28 TA6/7 patients had a higher risk of grade 3\~4 delayed-onset diarrhea as compared to *UGT1A1*\*28 TA6/6 patients, and the difference was statistically significant (χ2 = 4.884, *p* = 0.027). Meanwhile, *UGT1A1*\*28 TA6/7 was unlikely to increase the risk of grade 3\~4 neutropenia (χ2 = 2.844, *p* = 0.092). Among the 86 patients, there were 66 cases of *UGT1A1*\*6 G/G, of which six cases (9.1%) experienced grade 3\~4 delayed-onset diarrhea, and 10 cases (15.2%) had grade 3\~4 neutropenia. Among the 20 cases of *UGT1A1*\*6 G/A + A/A, nine cases (45.0%) had grade 3\~4 delayed-onset diarrhea and eight cases (40.0%) experienced grade 3\~4 neutropenia. Statistical analysis showed that *UGT1A1*\*6 G/A + A/A patients had a higher risk of grade 3\~4 diarrhea as compared to G/G patients, with statistically significant difference (χ2 = 11.364, *p* = 0.001), and also a higher risk of grade 3\~4 neutropenia as compared to G/G patients (χ2 = 5.727, *p* = 0.017). In this study, no patient suffered from adverse event-related death. (Table [3](#Tab3){ref-type="table"}). The delayed diarrhea and neutropenia was not associated with gender, age, PS score, primary lesion and the number of metastatic organs(*p* \> 0.05) (Table [4](#Tab4){ref-type="table"}), but associated with genotype((Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}; Table [6](#Tab6){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). The probability of occurrence of grade 3\~4 delayed diarrhea and neutropenia in wild-type patients was significantly lower than that in single-point and double-point mutants (χ2 = 8.802, *p* = 0.005, χ2 = 23.171, *p* = 0.000). **(**Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). Table 3Toxicity and UGT1A1 status (%)ToxicityUGT1A1\*28*P*UGT1A1\*6*P*TA6/6\
Number (%)TA6/7\
Number (%)G/G\
Number (%)G/A + A/A\
Number (%)Diarrhea 0 grade41 (68.3)10 (38.5)0.02745 (68.2)7 (35.0)0.001 1--2 grade12 (20.0)7 (26.9)15 (22.7)4 (20.0) 3--4 grade7 (11.7)9 (34.6)6 (9.1)9 (45.0)Neutropenia 0 grade33 (55.0)10 (38.4)0.09238 (57.6)5 (25.0)0.017 1--2 grade18 (30.0)8 (30.8)18 (27.3)7 (35.0) 3--4 grade9 (15.0)8 (30.8)10 (15.2)8 (40.0)Table 4Toxicity and clinical characteristicsClinical featureDiarrhea*P*Neutropenia*P*0 grade1--2 grade3--4 grade0 grade1--2 grade3--4 gradeAge (years)  \< 60311260.3322811100.235  ≥ 60217915148Gender Male3212100.9362715120.905 Female207516106PS score 017750.94713970.776 1351210301611Tumor site Colon23850.753181170.945 Rectum291110251411N of metastatic organs 1311280.8432515110.974 2217718107Table 5Multivariate analysis ofthe logistic risk ratio model for Delayed diarrheaDelayed diarrheaβSigExp(B)95% CILower BoundUpper BoundAge0.7490.2872.1150.5338.386Sex−0.6790.3810.5070.1112.386PS scores−0.3640.6430.6950.1493.242Primary origin0.2940.7001.3410.3015.982Number of organs with metastases0.7360.3172.0890.4938.844genotypa1.9040.0006.7102.50417.978constant−5.3370.0000.005Fig. 3Multiple factors analysis of delayed diarrhea by Logistic regressionTable 6Multivariate analysis of logistic risk ratio model for neutropenianeutropeniaβSigExp(B)95% CILower BoundUpper BoundAge−0.1070.8690.8990.2533.194Sex−0.4950.4730.6100.1582.353PS scores−0.5740.4210.5630.1392.281Primary origin0.4300.5301.5370.4025.879Number of organs with metastases0.4280.5271.5340.4085.770genotypa1.8980.0006.6712.70816.434constant−4.3620.0000.013Fig. 4Multiple factors analysis of neutropenia by Logistic regressionTable 7Delayed diarrheacompared withUGT1A1wild-type、single-point and double-point mutants (%)GenotypeTotal nDelayed diarrhea n(%)X^2^*P*UGT1A1\*280\~IIIII\~IV6.3080.0176/66053 (88.3)7 (11.7)6/72617 (65.4)9 (34.6)UGT1A1\*613.7450.001G/G6660 (90.9)6 (10.0)G/A + A/A2011(55.0)9 (24.3)Numbers of mutational alleles8.8020.005Double single type5350 (94.3)3 (5.7)Single variant2217(77.3)5 (22.7)Double variant117 (63.6)4 (36.3)Table 8Neutropenia compared withUGT1A1wild-type、single-point and double-point mutants (%)GenotypeTotal nneutropenia n(%)X^2^*P*UGT1A1\*280\~IIIII\~IV2.8440.1396/66051 (85.0)9 (15.0)6/72618 (69.2)8 (30.8)UGT1A1\*65.7270.027G/G6656 (84.8)10 (15.2)G/A + A/A2012 (60.0)8 (40.0)Numbers of mutational alleles23.1710.000Double single type5350 (94.3)3 (5.7)Single variant2213 (59.1)9 (40.9)Double variant114 (36.4)7 (63.6)

Response to chemotherapy based on the *UGT1A1* genotype {#Sec12}
-------------------------------------------------------

Among the 86 *UGT1A1*\*28 patients, there were two cases of CR (7.7%) (both of TA6/7), 32 cases of PR \[including 23 TA6/6 cases (38.3%) and nine TA6/7 cases (34.6%)\], 30 cases of SD \[including 21 TA6/6 cases (35.0%) and nine TA6/7 cases (34.6%)\], and 22 cases of PD \[including 16 TA6/6 cases (26.7%) and six TA6/7 cases (23.1%)\] (Fig. [5](#Fig5){ref-type="fig"}). Among the 86 *UGT1A1*\*6 patients, there were two cases of CR \[one G/G case (1.5%) and one G/A + A/A case (5.0%)\], 34 cases of PR \[including 26 G/G cases (39.4%) and eight G/A + A/A cases (40.0%)\], 28 cases of SD \[including 22 G/G cases (33.3%) and six G/A + A/A cases (30%)\], and 22 cases of PD \[including 17 G/G cases (25.8%) and five G/A + A/A cases (25%)\] (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). Of these, the ORRs of *UGT1A1*\*28 TA6/6 and TA6/7 patients after chemotherapy were 38.3 and 42.3% (χ2 = 0.120, *p* = 0.729), respectively, while those of *UGT1A1*\*6 G/G and G/A + A/A patients were 40.9 and 45.0% (χ2 = 0.106, *p* = 0.745), respectively. (Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}). Fig. 5Best percentage change of response to chemotherapy from baseline with *UGT1A1* genotypeTable 9Response to treatment and UGT1A1 status (%)EffectUGT1A1\*28*P*UGT1A1\*6*P*TA6/6 Number (%)TA6/7 Number (%)G/G Number (%)G/A + A/A Number (%)CR0 (0)2 (7.7)0.7291 (1.5)1 (5.0)0.745PR23 (38.3)9 (34.6)26 (39.4)8 (40.0)SD21 (35.0)9 (34.6)22 (33.3)6 (30.0)PD16 (26.7)6 (23.1)17 (25.8)5 (25.0)Table 10Response compared withUGT1A1wild-type、single-point and double-point mutants (%)GenotypeTotal nORR % (n)X^2^*P*DCR % (n)X^2^*P*UGT1A1\*280.1200.8120.1230.7946/66038.3 (23)73.3 (44)6/72642.3 (11)76.9 (20)UGT1A1\*60.1060.7990.0051.000G/G6640.9 (27)74.2 (49)G/A + A/A2045.0 (9)75.0 (15)Numbers of mutational alleles0.0691.0000.3290.879Double single type5341.5 (22)75.5 (40)Single variant2240.9(9)72.7 (16)Double variant1144.5 (5)81.8 (9)

Progression-free survival based on the *UGT1A1* genotype {#Sec13}
--------------------------------------------------------

Patients were followed-up until June 01, 2017. The median PFS of *UGT1A1*\*28 TA6/6 and TA6/7 patients were 7.0 and 7.4 months, respectively, with statistically insignificant difference (*p* = 0.427), and those of *UGT1A1*\*6 G/G and G/A + A/A patients were 6.9 and 7.0 months, respectively, with statistically insignificant difference (*p* = 0.408). The survival curves plotted using the Kaplan-Meier method are shown in Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}. Fig. 6Progression-Free Survival of patients with wild-type *UGT1A1* \* 28 and mutant-type *UGT1A1* \* 28Fig. 7Progression-Free Survival of patients with wild-type *UGT1A1* \* 6 and mutant-type *UGT1A1* \* 6

Distribution of the *UGT1A1* genotype with irinotecan dose reduction {#Sec14}
--------------------------------------------------------------------

Among the 86 patients, irinotecan dose was reduced in 15 patients, including six cases of wild-type (TA6/6) and nine cases of mutant-type (TA6/7) *UGT1A1*\*28, and seven cases of wild-type (G/G) and eight cases of mutant-type (G/A) *UGT1A1*\*6. This indicated that a higher ratio of patients with mutant-type *UGT1A1*\*28 and *UGT1A1*\*6 required irinotecan dose reduction as compared to patients with wild-type *UGT1A1*\*28 and *UGT1A1*\*6 (χ2 = 6.019, *p* = 0.014; χ2 = 7.281, *p* = 0.007) (Table [11](#Tab11){ref-type="table"}). During subsequent chemotherapy, the irinotecan dose was reduced by about 20%. Fifteen patients could tolerate the reduced dose of irinotecan, and did not require irinotecan dose reduction to the next gradient. Table 11Correlation between UGT1A1 genetic polymorphisms and irinotecan dose reduction in patients with CRCIrinotecan dose reductionUGT1A1\*28*P*UGT1A1\*6*P*TA6/6\
Number (%)TA6/7 + TA7/7\
Number (%)G/G\
Number (%)G/A\
Number (%)Yes6 (10.0)9 (45.0)0.0147 (10.6)8 (40.0)0.007No54 (90.0)11 (55.0)59 (89.4)12 (60.0)

Toxicity of irinotecan dose reduction based on the *UGT1A1* genotype {#Sec15}
--------------------------------------------------------------------

After the irinotecan dose was reduced, the incidences of grade 3\~4 diarrhea and grade 3\~4 neutropenia were significantly decreased in both the dose reduction group and non-dose reduction group for patients with *UGT1A1*\*28 (*p* = 1.000; *p* = 0.613) and *UGT1A1*\*6 (*p* = 0.442; *p* = 0.139) in Table [12](#Tab12){ref-type="table"}. Table 12Toxicity with irinotecan dose reduction and UGT1A1 status (%)ToxicityUGT1A1\*28UGT1A1\*6Dose reductionNon-dose reductionDose reductionNon-dose reductionDiarrhea 0 grade6 (40.0)47 (66.2)8 (53.3)45 (63.4) 1--2 grade9 (60.0)21 (29.6)6 (40.0)24 (33.8) 3--4 grade0 (0.0)3 (4.2)1 (6.7)2 (2.8)Neutropenia 0 grade9 (60.0)45 (63.4)9 (60.0)48 (67.6) 1--2 grade5 (33.3)21 (29.6)4 (26.7)21 (29.6) 3--4 grade1 (6.7)5 (7.0)2 (13.3)2 (2.8)

Efficacy of irinotecan dose reduction based on the *UGT1A1* genotype {#Sec16}
--------------------------------------------------------------------

In patients with *UGT1A1*\*28 and *UGT1A1*\*6 genes, there was insignificant difference in the short-term effect between the dose reduction group and non-dose reduction group (*p* = 0.402, *p* = 0.368) **(**Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}**)**. Also, there was insignificant difference in the median PFS between the dose reduction group and non-dose reduction group (χ2 = 1.946, *p* = 0.378; χ2 = 1.895, *p* = 0.388) (Table [13](#Tab13){ref-type="table"}). Fig. 8Comparison of long-term effects between the dose reduction group and non-reduction group in patients with *UGT1A1* \* 28 geneFig. 9Comparison of long-term effect between the dose reduction group and non-reduction group in patients with *UGT1A1* \* 6 geneTable 13Comparison of short-term effects between the irinotecan dose reduction group and non-dose reduction groupEffectUGT1A1\*28*p*UGT1A1\*6*p*Dose reductionNon-dose reductionDose reductionNon-dose reductionPR2 (13.3)11 (15.5)0.3784 (26.7)9 (12.7)0.388SD9 (60.0)29 (40.8)6 (40.0)33 (46.5)PD4 (26.7)31 (43.7)5 (33.3)29 (40.8)

Discussion {#Sec17}
==========

Irinotecan is a semi-synthetic derivative of natural camptothecin, and has been widely used in the treatment of solid tumors such as gastric cancer, colorectal cancer (CRC), lung cancer, etc. A combination of irinotecan and fluorouracil is a standard first-line regimen for advanced CRC, especially advanced CRC with rapid progression, with an efficacy rate of up to 40% \[[@CR10]--[@CR12]\]. However, this regimen has two major adverse reactions of delayed-onset diarrhea and neutropenia, where the incidences of grade 3\~4 neutropenia and severe diarrhea are 45% and 20\~40% \[[@CR13]\], respectively, which limits its clinical application and exhibits inter-individual variations.

Irinotecan is hydrolyzed in vivo by carboxylesterase (CE) into an active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). The latter is a topoisomerase I inhibitor that inhibits repair of broken single-stranded DNA, disrupts DNA replication and transcription, and exerts cytotoxic effects. SN-38 is inactivated by *UGT1A1* as glucuronic acid product SN-38G, which is excreted into the intestine through the bile and is transformed into SN-38 by the intestinal bacterial β-glucuronidase, thereby inducing mucosal injury and delayed-onset diarrhea. *UGT1A1* enzyme in the intestine can re-catalyze SN-38 for SN-38G detoxification. Therefore, the adverse reactions of irinotecan are related to its main drug-metabolizing enzyme *UGT1A1*, whose activity is affected by polymorphism. *UGT1A1*\*28 polymorphism and irinotecan-related adverse reactions have been reported in many studies, but the correlation between *UGT1A1*\*6 polymorphism and adverse reactions of irinotecan remains unclear. Several studies, with conflicting results, have indicated that the *UGT1A1* polymorphism has insufficient sensitivity and specificity in predicting the adverse effects of irinotecan. The results of different ethnic groups in the same race are rarely reported. In addition, the role of *UGT1A1* polymorphism in predicting the toxicity in patients receiving different doses of irinotecan is clinically controversial.

Due to differences in genetic background, different *UGT1A1* mutation sites exist among various ethnic groups, which is responsible for different incidences of toxicity between different populations in eastern and western countries receiving irinotecan treatment. Studies on the distribution of *UGT1A1* \*28 and \*6 polymorphisms have demonstrated that *UGT1A1* \* 28 homozygous mutant TA7/7 accounts for 10\~15% and 12\~27% in the Caucasian and African populations, respectively \[[@CR14], [@CR15]\], while its mutation rate is only 1.2\~4.7% in Asian population \[[@CR16], [@CR17]\]. Nakaura et al. \[[@CR18]\] showed that the wild-type *UGT1A1*\*28 accounted for 46 and 76% in the Caucasian and Asian populations, respectively, indicating significant inter-ethnic differences. Etienne-Grimald et al. \[[@CR19]\] concluded that *UGT1A1*\*28 had the highest expression frequency in Americans and Caucasians, accounting for 38\~45% and 29\~39%, respectively, while a mutation frequency of about 15\~18% in Asians, of which the homozygous mutation type accounted for 3%. Zhang et al. \[[@CR20]\] investigated the distribution of *UGT1A1*\*28 polymorphism in 517 Han patients, and found that *UGT1A1*\*28 TA6/6, TA7/6 and TA7/7 accounted for 77.2, 22 and 0.8%, respectively. In this study, the distribution frequencies of wild-type and heterozygous-type *UGT1A1*\*28 were 69.8 and 30.2%, respectively, in 86 patients in Guangxi Zhuang, with no homozygous-type case, which indicated that the homozygous mutation rate was further reduced as compared to the Asian Han ethnicity.

*UGT1A1*\*6 is a unique *UGT1A1* mutation type in Asian populations. The frequencies of *UGT1A1*\*6 homozygous mutant A/A in Koreans and Japanese were reported to be 7 and 4%, respectively, while the frequencies of *UGT1A1*\*6 G/G, G/A and A/A in Han Chinese were 66.9, 29.3 and 3.8%, respectively \[[@CR20]\]. This study revealed that the frequencies of wild-type, heterozygous-type and homozygous-type *UGT1A1*\*6 in Guangxi Zhuang were 76.7, 20.9 and 2.3%, respectively, which differed from the reported distribution frequencies of genetic polymorphisms in Europeans and Americans, wherein the mutation rate was slightly lower than that in Chinese Han and other Asians. However, this may be due to a small sample size. Equilibrium test of *UGT1A1*\*28 and *UGT1A1*\*6 allelic frequencies in this study revealed that the samples were in accordance with the Hardy-Weinberg equilibrium, derived from a larger and randomized marriage-balanced population, and was representative.

Clinical studies have shown that Caucasians with *UGT1A1*\*28 gene mutants (TA6/7 and TA7/7) have a higher risk of severe granulocytopenia and diarrhea than those with wild-type *UGT1A1*\*28 (TA6 /6) after receiving irinotecan \[[@CR21]\]. In our study, Guangxi Zhuang patients with *UGT1A1*\*28 mutations showed a higher risk of 3\~4 grade delayed-onset diarrhea as compared to those with wild-type *UGT1A1*\*28 (30.8% vs. 11.7%, *p* = 0.044), but did not have a higher risk of 3\~4 grade neutropenia (34.6% vs. 15.0%, *p* = 0.112), which was consistent with other domestic reports \[[@CR22]\]. Moreover, Guangxi Zhuang patients with *UGT1A1*\*6 mutations had a higher risk of 3\~4 grade delayed-onset diarrhea after receiving irinotecan (45% vs. 9.1%, *p* = 0.001), and an increased risk of 3\~4 grade neutropenia (40% vs. 15.2%, *p* = 0.017), which was consistent with numerous clinical studies in Japan \[[@CR23]--[@CR25]\]. The correlation between *UGT1A1* genotype and adverse reactions of irinotecan remains controversial. For the effect of *UGT1A1*\* 28 mutant on delayed-onset diarrhea and 3\~4 grade granulocytopenia, only one adverse reaction was mentioned in some studies. For example, Miyata et al. only compared the risk of neutropenia, but not the risk of delayed-onset diarrhea \[[@CR26]\]. Also, the predictive effects were refuted in some studies, but supported in other studies. Some studies supported the predictive effect on 3\~4 grade neutropenia but refuted the risk of delayed-onset diarrhea \[[@CR17]\], while others supported the occurrence of delayed-onset diarrhea but refuted the risk of 3\~4 grade neutropenia \[[@CR22]\]. In addition to the racial differences, we believe it is also related to the dose of irinotecan. In many studies, Caucasians were enrolled and a larger initial dose of irinotecan may have been selected, but the dose of irinotecan was not investigated. Previous studies revealed that *UGT1A1*\*28 and *UGT1A1*\*6 have a predictive effect on the adverse reactions of intermediate or high dose of irinotecan, but not on a low dose of irinotecan \[[@CR27]\]. In this study, the homozygous and heterozygous mutations of *UGT1A1* showed a predictive effect when the dose of irinotecan was reduced. For *UGT1A1*\*28 and *UGT1A1*\*6, the incidence of 3\~4 grade neutropenia and 3\~4 grade diarrhea significantly declined in both the dose reduction and non-reduction groups.

The correlation between *UGT1A1* gene polymorphism and efficacy of irinotecan chemotherapy remains inconclusive. Toffoli et al. \[[@CR28]\] believed that the efficacy was better in patients with mutant *UGT1A1*\*28 as compared to those with wild-type *UGT1A1*\*28. However, others believed that the efficacy was better in wild-type patients as compared to mutant patients \[[@CR29]\], or the *UGT1A1* gene polymorphism was not correlated with the efficacy \[[@CR30]\]. The relationship between *UGT1A1* gene polymorphism and adverse reactions of chemotherapy has been reported in several studies, while the efficacy of chemotherapy has been rarely studied. This study showed that the polymorphism of *UGT1A1*\*28 and *UGT1A1*\*6 genes in Guangxi Zhuang patients with CRC was not significantly correlated with the RR and median PFS of irinotecan chemotherapy. Nevertheless, the correlation between *UGT1A1* polymorphism and efficacy of irinotecan chemotherapy needs further verification with a large sample size study.

The above results may be affected by differences in population, drug dose, and a small sample size. Whether the gene polymorphism distribution and inter-individual variations in response to irinotecan in Chinese Zhuang are different from that in Han as well as European and American populations remains unknown. The sample size should be increased and the follow-up survival should be analyzed based on the gene distribution characteristics of Chinese and combined with the drug dose, in order to achieve the goal of individualization.

Conclusions {#Sec18}
===========

The frequency of gene mutation differs among various ethnic groups due to different genetic backgrounds. In our study, we found the distribution frequencies of wild-type, heterozygous-type and homozygous-type *UGT1A1* in Guangxi Zhuang patients of metastatic colorectal cancer differed from the reported distribution frequencies of genetic polymorphisms in European patients people and Chinese Han patients. The *UGT1A1* gene polymorphism with irinotecan chemotherapy-associated diarrhea and neutropenia were closely related. Guangxi Zhuang patients of metastatic colorectal cancer with *UGT1A1*\*28 mutations showed a higher risk of 3\~4 grade diarrhea as compared to those with wild-type *UGT1A1*\*28 which did not increase the risk of grade 3\~4 neutropenia. Moreover, Guangxi Zhuang patients with *UGT1A1*\*6 mutations had a higher risk of 3\~4 grade diarrhea and neutropenia those with wild-type. After chemotherapy with FOLFIRI, there was no significant difference in response rate and the median progression-free survival between the wild-type, mutant treatment of *UGT1A1* \* 28 and *UGT1A1* \* 6. The above results may be affected by differences in population, or drug dose. The follow-up survival should be analyzed based on the gene distribution characteristics of Chinese and combined with the drug dose, in order to achieve the goal of individualization.

CE

:   Carboxylesterase

CRC

:   Colorectal cancer

HWE

:   Hardy-Weinberg equilibrium

mCRC

:   Metastatic colorectal cancer

mPFS

:   Median progression-free survival

RR

:   Response rate

*UGT1A1*

:   Uridine diphosphate glucuronosyl transferase 1A1
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